Shanghai HeartCare Medical Technology Corporation Limited announced that the Company has recently received the approval from the National Medical Products Administration of the PRC ("NMPA") for the registration application for the LAA Occluder, making it the Company's 14th NMPA approved product as well as the fifth product approved in 2022. LAA Occluder is one of the Company ' s ischemic stroke prevention devices, and the Core Product (within the meaning ascribed thereto in Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")). The LAA Occluder is a stroke prevention device designed to be permanently implanted at the opening of the LAA of patients with non-valvular atrial fibrillation (AF) to prevent thrombus escaping from the LAA, thus causing embolization.

LAA occlusion is a one-time surgical therapy with proven efficacy, in particular for the patient who is not suitable for long-term oral anticoagulation therapy and has a higher risk for bleeding complications.